Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.71 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.71 |
| ▸ | MEF2D | Q14814 | 2/20 | 0.55 |
| ▸ | EP300 | Q09472 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.50 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5326785 | 1.00 | HDAC1 (0.71) | HDAC1HDAC4HDAC6MEF2DEP300 | |
| SCHEMBL14345654 | 0.89 | HDAC1 (0.65) | HDAC1HDAC4HDAC6MEF2DEP300 | |
| SCHEMBL8118903 | 0.89 | HDAC1 (0.65) | HDAC1HDAC4HDAC6MEF2DEP300 | |
| SCHEMBL4828500 | 0.89 | HDAC1 (0.78) | HDAC1HDAC4HDAC6MEF2DEP300 | |
| SCHEMBL8261388 | 0.88 | HDAC1 (0.78) | HDAC1HDAC4HDAC6MEF2DEP300 | |
| SCHEMBL5280493 | 0.88 | HDAC1 (0.60) | HDAC1HDAC4HDAC6MEF2DEP300 | |
| SCHEMBL5280487 | 0.88 | HDAC1 (0.60) | HDAC1HDAC4HDAC6MEF2DEP300 | |
| SCHEMBL8260908 | 0.86 | HDAC1 (0.73) | HDAC1HDAC4HDAC6MEF2DEP300 | |
| SCHEMBL5330916 | 0.85 | HDAC4 (0.54) | HDAC1HDAC4HDAC6MEF2DEP300 | |
| SCHEMBL5330900 | 0.85 | HDAC4 (0.54) | HDAC1HDAC4HDAC6MEF2DEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007143822-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HAT1 | HDAC1 1/4885HDAC4 12/4885HDAC6 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.